These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25312653)

  • 1. Improving chemoradiation efficacy by PI3-K/AKT inhibition.
    Stegeman H; Span PN; Kaanders JH; Bussink J
    Cancer Treat Rev; 2014 Dec; 40(10):1182-91. PubMed ID: 25312653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer.
    Schuurbiers OC; Kaanders JH; van der Heijden HF; Dekhuijzen RP; Oyen WJ; Bussink J
    J Thorac Oncol; 2009 Jun; 4(6):761-7. PubMed ID: 19404218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.
    Bussink J; van der Kogel AJ; Kaanders JH
    Lancet Oncol; 2008 Mar; 9(3):288-96. PubMed ID: 18308254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways.
    Bouchard V; Demers MJ; Thibodeau S; Laquerre V; Fujita N; Tsuruo T; Beaulieu JF; Gauthier R; Vézina A; Villeneuve L; Vachon PH
    J Cell Physiol; 2007 Sep; 212(3):717-28. PubMed ID: 17443665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
    Demers MJ; Thibodeau S; Noël D; Fujita N; Tsuruo T; Gauthier R; Arguin M; Vachon PH
    J Cell Biochem; 2009 Jul; 107(4):639-54. PubMed ID: 19479902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
    O' Neill C
    Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappaB signaling pathway.
    Rong R; He Q; Liu Y; Sheikh MS; Huang Y
    Oncogene; 2002 Feb; 21(7):1062-70. PubMed ID: 11850823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
    Li L; Ittmann MM; Ayala G; Tsai MJ; Amato RJ; Wheeler TM; Miles BJ; Kadmon D; Thompson TC
    Prostate Cancer Prostatic Dis; 2005; 8(2):108-18. PubMed ID: 15724144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
    Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
    Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphatidylinositol 3' kinase-Akt-mammalian target of rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and their clinicopathologic implications.
    Fadare O; Renshaw I; Olson SJ; Liang SX
    Int J Gynecol Pathol; 2011 May; 30(3):244-51. PubMed ID: 21464729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
    Harvey RD; Lonial S
    Future Oncol; 2007 Dec; 3(6):639-47. PubMed ID: 18041916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway.
    Anastasius N; Boston S; Lacey M; Storing N; Whitehead SA
    J Steroid Biochem Mol Biol; 2009 Aug; 116(1-2):50-5. PubMed ID: 19406242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hypoxia/reoxygenation-induced oxidative stress in HGF-stimulated antiapoptotic signaling: role of PI3-K and Akt kinase upon rac1.
    Ozaki M; Haga S; Zhang HQ; Irani K; Suzuki S
    Cell Death Differ; 2003 May; 10(5):508-15. PubMed ID: 12728249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
    Zhao YW; Jin L; Li ZM; Zhao CJ; Wei YQ; Yang HS
    Cancer Sci; 2011 Aug; 102(8):1469-75. PubMed ID: 21561530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells.
    Su JC; Lin KL; Chien CM; Chuang PW; Chang LS; Lin SR
    Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):833-40. PubMed ID: 20456425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways.
    Harnois C; Demers MJ; Bouchard V; Vallée K; Gagné D; Fujita N; Tsuruo T; Vézina A; Beaulieu JF; Côté A; Vachon PH
    J Cell Physiol; 2004 Feb; 198(2):209-22. PubMed ID: 14603523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of nuclear estrogen receptors induced by low-power laser irradiation via PI3-K/Akt signaling cascade.
    Huang L; Tang Y; Xing D
    J Cell Physiol; 2013 May; 228(5):1045-59. PubMed ID: 23065720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.